Skip to main content
SpringerLink
Log in

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumour scintigraphy and radionuclide therapy. The kidney is the most important critical organ during such therapy owing to the reabsorption and retention of radiolabelled peptides. The aim of this study was to investigate in a rat model both the localisation and the mechanism of renal uptake after intravenous injection of radiolabelled somatostatin analogues. The multi-ligand megalin/cubilin receptor complex, responsible for reabsorption of many peptides and proteins in the kidney, is an interesting candidate for renal endocytosis of these peptide analogues.

Methods

For localisation studies, ex vivo autoradiography and micro-autoradiography of rat kidneys were performed 1–24 h after injection of radiolabelled somatostatin analogues and compared with the renal anti-megalin immunohistochemical staining pattern. To confirm a role of megalin in the mechanism of renal retention of [111In-DTPA]octreotide, the effects of three inhibitory substances were explored in rats.

Results

Renal ex vivo autoradiography showed high cortical radioactivity and lower radioactivity in the outer medulla. The distribution of cortical radioactivity was inhomogeneous. Micro-autoradiography indicated that radioactivity was only retained in the proximal tubules. The anti-megalin immunohistochemical staining pattern showed a strong similarity with the renal [111In-DTPA]octreotide ex vivo autoradiograms. Biodistribution studies showed that co-injection of positively charged d-lysine reduced renal uptake to 60% of control. Sodium maleate reduced renal [111In-DTPA]octreotide uptake to 15% of control. Finally, cisplatin pre-treatment of rats reduced kidney uptake to 70% of control.

Conclusion

Renal retention of [111In-DTPA]octreotide is confined to proximal tubules in the rat kidney, in which megalin-mediated endocytosis may play an important part.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  1. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716–31

    CAS  PubMed  Google Scholar 

  2. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84–91

    Article  PubMed  Google Scholar 

  3. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463–9

    PubMed  Google Scholar 

  4. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234–45

    Article  CAS  PubMed  Google Scholar 

  5. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–47

    Article  CAS  PubMed  Google Scholar 

  6. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426–34

    CAS  Google Scholar 

  7. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–22

    CAS  PubMed  Google Scholar 

  8. De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med 2004;45:1168–71

    PubMed  Google Scholar 

  9. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004;19:159–70

    Article  CAS  PubMed  Google Scholar 

  10. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001;280:F562–73

    CAS  PubMed  Google Scholar 

  11. Verroust PJ, Christensen EI. Megalin and cubilin—the story of two multipurpose receptors unfolds. Nephrol Dial Transplant 2002;17:1867–71

    Article  CAS  PubMed  Google Scholar 

  12. Christensen EI, Nielsen S, Moestrup SK, Borre C, Maunsbach AB, de Heer E, et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol 1995;66:349–64

    CAS  PubMed  Google Scholar 

  13. Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, et al. In vivo application of [111In-DTPA-d-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593–601

    Article  CAS  PubMed  Google Scholar 

  14. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628–33

    Article  PubMed  Google Scholar 

  15. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917–20

    CAS  PubMed  Google Scholar 

  16. de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437–41

    PubMed  Google Scholar 

  17. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Uehara T, et al. Significance of 111In-DTPA chelate in renal radioactivity levels of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:459–68

    Article  CAS  PubMed  Google Scholar 

  18. Ten Bokum AM, Rosmalen JG, Hofland LJ, Krenning EP, Van Hagen PM, Breeman WA. Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity. Nucl Med Commun 2002;23:1009–17

    Article  CAS  PubMed  Google Scholar 

  19. Mogensen CE, Solling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37:477–86

    Google Scholar 

  20. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201–12

    Article  CAS  PubMed  Google Scholar 

  21. Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-d-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003;44:1315–21

    CAS  PubMed  Google Scholar 

  22. Christensen EI, Rennke HG, Carone FA. Renal tubular uptake of protein: effect of molecular charge. Am J Physiol 1983;244:F436–41

    CAS  PubMed  Google Scholar 

  23. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:761–8

    Article  CAS  PubMed  Google Scholar 

  24. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929–33

    CAS  PubMed  Google Scholar 

  25. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825–34

    CAS  PubMed  Google Scholar 

  26. Kramer JH, Gonick HC. Experimental Fanconi syndrome: I. Effect of maleic acid on renal cortical Na–K-ATPase activity and ATP levels. J Lab Clin Med 1970;76:799–808

    CAS  PubMed  Google Scholar 

  27. Nagai J, Tanaka H Nakanishi N, Murakami T, Takano M. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001;281:F337–44

    CAS  PubMed  Google Scholar 

  28. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388–92

    PubMed  Google Scholar 

  29. Rolleman EJ, Krenning EP, Van Gameren A, Bernard BF, De Jong M. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 2004;45:709–13

    CAS  PubMed  Google Scholar 

  30. Gutmann EJ, Niles JL, McCluskey RT, Brown D. Colchicine-induced redistribution of an apical membrane glycoprotein (gp330) in proximal tubules. Am J Physiol 1989;257:C397–407

    CAS  PubMed  Google Scholar 

  31. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis 1986;8:356–67

    CAS  PubMed  Google Scholar 

  32. Takano M, Nakanishi N, Kitahara Y, Sasaki Y, Murakami T, Nagai J. Cisplatin-induced inhibition of receptor-mediated endocytosis of protein in the kidney. Kidney Int 2002;62:1707–17

    Article  CAS  PubMed  Google Scholar 

  33. Choie DD, Longnecker DS, del Campo AA. Acute and chronic cisplatin nephropathy in rats. Lab Invest 1981;44:397–402

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Katy van der Wansem and Magda Bijster for their expert technical assistance in preparing micro-autoradiograms.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands

    Marleen Melis, Eric P. Krenning, Bert F. Bernard & Marion de Jong

  2. Centre of Nuclear Medicine and Laboratory of PET, UCL, Brussels, Belgium

    Raffaella Barone

  3. Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands

    Theo J. Visser

Authors
  1. Marleen Melis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric P. Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bert F. Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raffaella Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Theo J. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marion de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marion de Jong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melis, M., Krenning, E.P., Bernard, B.F. et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 32, 1136–1143 (2005). https://doi.org/10.1007/s00259-005-1793-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1793-0

Keywords

Search

Navigation